Table 2 Associations between baseline characteristics and (a) CART-derived AUC0-24h/MICBMD and AUC24-48h/MICBMD groups and (b) emergence of hVISA
AUC0-24h/MICBMD < 521 (N = 52) | AUC24-48h/MICBMD ≥ 521 (N = 67) | AUC24-48h/MICBMD < 650 (N = 54) | AUC24-48h/MICBMD ≥ 650 (N = 65) | Non-hVISA (N = 112) | hVISA (N = 7) | |
|---|---|---|---|---|---|---|
Age in years, mean (SD) | 57.1 (15.6)** | 64.5 (14.6)** | 58.0 (17.1)* | 64.0 (14.4)* | 60.8 (15.6) | 68.4 (10.9) |
Sex-male | 34 (65.4) | 49 (73.1) | 39 (72.2) | 44 (67.7) | 76 (67.9)1* | 7 (100)* |
Weight in kg, mean (SD) | 86.5 (28.3) | 82.6 (31.7) | 84.7 (27.9) | 84.4 (33.0) | 84.0 (30.7) | 89.5 (20.5) |
Recent residence in healthcare institution in previous 6 months | 30 (57.5) | 43 (64.2) | 27 (50.0) | 40 (61.5) | 68 (60.7) | 5 (71.4) |
Diabetes mellitus | 19 (36.5) | 33 (49.3)* | 21 (38.9) | 31 (47.7) | 48 (42.9) | 4 (57.1) |
Heart failure | 11 (21.2) | 27 (40.3)** | 13 (24.1)* | 25 (38.5)* | 37 (33.0) | 1 (2.6) |
COPD | 12 (23.1) | 26 (38.8)* | 17 (31.5) | 21 (32.3) | 35 (31.3) | 3 (42.9) |
Hepatic dysfunction | 1 (1.9) | 4 (6.0) | 1 (1.9) | 4 (6.2) | 5 (4.5) | 0 (0.0) |
Malignancy | 19 (36.5) | 14 (20.9)* | 17 (31.5) | 16 (24.6) | 30 (26.8) | 3 (42.9) |
Decubitus ulcers | 11 (21.2) | 14 (20.9) | 12 (22.2) | 13 (20.0) | 24 (21.4) | 1 (14.3) |
Immunosuppressants | 13 (25.0) | 10 (14.9) | 12 (22.2) | 11 (16.9) | 20 (17.9)* | 3 (42.9)* |
HIV | 3 (5.8) | 1 (1.5) | 3 (5.6) | 1 (1.5) | 4 (3.6) | 0 (0.0) |
History of cerebrovascular event | 5 (9.6) | 8 (11.9) | 5 (9.3) | 8 (12.3) | 13 (11.6) | 0 (0.0) |
Recent surgery in previous 30 days | 21 (40.4) | 19 (28.4)* | 26 (48.1)** | 14 (21.5)** | 36 (32.1) | 4 (57.1) |
Recent antibiotics in previous 30 days | 29 (55.8) | 36 (53.7) | 29 (53.7) | 36 (55.4) | 62 (55.4) | 3 (42.9) |
Prior vancomycin in past 30 days | 11 (21.2) | 9 (13.4) | 10 (18.5) | 10 (15.4) | 20 (17.9) | 0 (0.0) |
Length of stay in days prior to index culture collection, median (IQR) days | 2 (0–14) | 1 (0–12) | 3 (0–19) | 1 (0–13) | 3 (0–14)* | 0 (0–0)* |
Intensive care unit at onset | 15 (28.8) | 26 (38.8) | 18 (33.3) | 23 (35.4) | 40 (35.7) | 1 (14.3) |
Baseline CLCR in mL/min, mean (SD) | 77.8 (56.8) | 71.1 (46.9) | 80.1 (58.4) | 69.8 (47.0) | 76.7 (51.5)** | 30.4 (17.8)** |
APACHE-II Score, mean (SD) | 13.3 (5.6) | 14.4 (6.5) | 14.2 (6.2) | 14.1 (6.0) | 13.7 (6.1)* | 17.7 (4.5)* |
MICBMD ≥ 1 mg/L | 16 (30.8)** | 8 (9.0)** | 16 (29.6)** | 6 (9.2)** | 18 (16.1)** | 4 (57.1)** |
MICEtest ≥ 1.5 mg/L | 35 (67.3)* | 35 (52.2)* | 35 (64.8) | 35 (53.8) | 65 (58.0) | 5 (71.4) |
Source of bloodstream infection | ||||||
• Intravenous catheter | 25 (48.1)* | 24 (35.8)* | 23 (42.6) | 26 (40.0) | 48 (42.9) | 1 (14.3) |
• Skin and soft tissue | 13 (25.0) | 14 (20.9) | 15 (27.8) | 12 (18.5) | 23 (20.5)** | 4 (57.1)** |
• Bone and joint | 2 (3.8) | 6 (9.0) | 2 (3.7) | 6 (9.2) | 8 (7.1) | 0 (0.0) |
• Respiratory tract | 2 (3.8) | 7 (10.4) | 2 (3.7)* | 7 (10.8)* | 9 (8.0) | 0 (0.0) |
• Intra-abdominal | 3 (5.8) | 4 (6.0) | 4 (7.4) | 3 (4.6) | 6 (5.4) | 1 (14.3) |
• Urinary tract | 1 (1.9) | 1 (1.5) | 1 (1.9) | 1 (1.5) | 2 (1.8) | 0 (0.0) |
• Infected graft/device | 2 (3.8) | 5 (7.5) | 2 (3.7) | 5 (7.7) | 5 (5.4) | 1 (14.3) |
• Unknown | 4 (7.7) | 6 (9.0) | 5 (9.3) | 5 (7.7) | 10 (8.9) | 0 (0.0) |
Presence of Infective Endocarditis | 9 (17.3) | 8 (11.9) | 9 (16.7) | 8 (12.3) | 14 (12.6)* | 3 (42.9)* |